Colorectal Cancer and Advanced Precancerous Neoplasm Screening Using Stool DNA-based SDC2 and SFRP2 Methylation Test in China, a Multi-Center Study
试验速览
- 阶段
- 不适用
- 入组人数
- 4,800
- 主要终点
- Sensitivity, specificity, positive predictive value and negative predictive value of bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) with comparison to colonoscopy, both with respect to cancer and advanced precancerous neoplasm.
研究概览
简要总结
The primary objective is to determine sensitivity, specificity, positive predictive value and negative predictive value of a bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) for colorectal cancer and advanced precancerous neoplasm(including advanced adenoma and advanced serrated lesions) screening, using colonoscopy as the reference method. Lesions will be confirmed as malignant or precancerous by histopathologic examination.
The secondary objective is to compare the performance of the bi-target stool DNA testing to a commercially available fecal immunochemical test (FIT) assay, both with respect to cancer and advanced precancerous neoplasm. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.
详细描述
This study is a multi-center diagnostic test led by the National Clinical Research Center for Digestive Disease (Shanghai) (Department of Gastroenterology, Changhai Hospital, Navy/Second Military Medical University), which is conducted at about 30 digestive endoscopy centers nationwide in China, with the expectation of including approximately 4,800 patients. Subjects willing to conduct colonoscopy examination will be asked to collect stool sample prior to bowl preparation for stool DNA test and commercially available FIT assay. The basic characteristics of subjects, bowel preparation method and quality, and related information of colonoscopy are recorded in detail. Colonoscopy and histopathologic examination are used as reference.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 40 to 85 years old, the gender is not limited
- •Willing to provide written consent
- •Able to provide stool sample
排除标准
- •Unwilling to provide stool samples
- •Subject with contraindications for bowel preparation or colonoscopy
- •Subject with known colorectal polyps but not removed
- •Subject with inflammatory bowel disease
- •History of colonoscopy within 1 year
- •History of colorectal cancer
- •History of hereditary colorectal cancer syndrome (including polyposis)
- •Active lower gastrointestinal bleeding
- •Subject taking anticoagulants such as aspirin and warfarin, or who have coagulopathy
- •Subject clinically highly suspected with gastrointestinal cancer
- •Other conditions deemed not suited for the study by investigators
- •Elimination Criteria:
- •Ask to withdraw from the study
- •Unable to get a stool sample
- •Invalid stool samples to test
- •Poor or inadequate bowel preparation
- •Failed to complete the colonoscopy
结局指标
主要结局
Sensitivity, specificity, positive predictive value and negative predictive value of bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) with comparison to colonoscopy, both with respect to cancer and advanced precancerous neoplasm.
时间窗: Through study completion, an average of 1 year
A diagnostic colonoscopy procedure is the reference method. Lesions will be confirmed as malignant or precancerous by histopathologic examination. Advanced precancerous neoplasm includes both advanced adenoma and advanced serrated lesions. The DNA test includes the methylation status of SDC2 and SFRP2. The tests were processed independently of colonoscopy procedure.
次要结局
- To compare the performance of the bi-target stool DNA testing to a commercially available FIT assay, both with respect to cancer and advanced precancerous neoplasm.(Through study completion, an average of 1 year)
研究者
Zhaoshen Li
MD, Director, Head of Department of Gastroenterology and Digestive Endoscopy Center, Principal Investigator, Clinical Professor
Changhai Hospital